Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Jun 19;18(1):283.
doi: 10.1186/s13063-017-2010-8.

Emergency treatment with levetiracetam or phenytoin in status epilepticus in children-the EcLiPSE study: study protocol for a randomised controlled trial

Mark D Lyttle  1   2 , Carrol Gamble  3 , Shrouk Messahel  4 , Helen Hickey  5 , Anand Iyer  4 , Kerry Woolfall  6 , Amy Humphreys  5 , Naomi E A Bacon  3 , Louise Roper  6 , Franz E Babl  7   8   9 , Stuart R Dalziel  10   11 , Mary Ryan  4 , Richard E Appleton  12 ; supported by Paediatric Emergency Research in the United Kingdom & Ireland (PERUKI)
Affiliations
Clinical Trial

Emergency treatment with levetiracetam or phenytoin in status epilepticus in children-the EcLiPSE study: study protocol for a randomised controlled trial

Mark D Lyttle et al. Trials. .

Abstract

Background: Convulsive status epilepticus (CSE) is the most common life-threatening neurological emergency in childhood. These children are also at risk of significant morbidity, with acute and chronic impact on the family and the health and social care systems. The current recommended first-choice, second-line treatment in children aged 6 months and above is intravenous phenytoin (fosphenytoin in the USA), although there is a lack of evidence for its use and it is associated with significant side effects. Emerging evidence suggests that intravenous levetiracetam may be effective as a second-line agent for CSE, and fewer adverse effects have been described. This trial therefore aims to determine whether intravenous phenytoin or levetiracetam is more effective, and safer, in treating childhood CSE.

Methods/design: This is a phase IV, multi-centre, parallel group, randomised controlled, open-label trial. Following treatment for CSE with first-line treatment, children with ongoing seizures are randomised to receive either phenytoin (20 mg/kg, maximum 2 g) or levetiracetam (40 mg/kg, maximum 2.5 g) intravenously. The primary outcome measure is the cessation of all visible signs of CSE as determined by the treating clinician. Secondary outcome measures include the need for further anti-seizure medications or rapid sequence induction for ongoing CSE, admission to critical care areas, and serious adverse reactions. Patients are recruited without prior consent, with deferred consent sought at an appropriate time for the family. The primary analysis will be by intention-to-treat. The primary outcome is a time to event outcome and a sample size of 140 participants in each group will have 80% power to detect an increase in CSE cessation rates from 60% to 75%. Our total sample size of 308 randomised and treated participants will allow for 10% loss to follow-up.

Discussion: This clinical trial will determine whether phenytoin or levetiracetam is more effective as an intravenous second-line agent for CSE, and provide evidence for management recommendations. In addition, this trial will also provide data on which of these therapies is safer in this setting.

Trial registration: ISRCTN identifier, ISRCTN22567894 . Registered on 27 August 2015 EudraCT identifier, 2014-002188-13 . Registered on 21 May 2014 NIHR HTA Grant: 12/127/134.

Keywords: Levetiracetam; Paediatric; Phenytoin; Randomised; Seizure; Status epilepticus; Trial.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Emergency treatment with Levetiracetam or Phenytoin in Status Epilepticus in children (EcLiPSE) study flowchart. CSE convulsive status epilepticus
Fig. 2
Fig. 2
Schematic of Emergency treatment with Levetiracetam or Phenytoin in Status Epilepticus in children (EcLiPSE) study design. 1Administration of the first-line treatment may have occurred prior to arrival in the ED. 2If a patient is randomised but not treated with a second-line anticonvulsant, follow-up would end at this point. APLS advanced paediatric life support, CRF case report form, ED Emergency Department
Fig. 3
Fig. 3
Emergency treatment with Levetiracetam or Phenytoin in Status Epilepticus in children (EcLiPSE) study assessments. *This physical examination should include a comment on any focal neurological signs. CRF case report form, X as indicated/appropriate
See this image and copyright information in PMC

References

    1. Novorol CL, Chin RFM, Scott RC. Outcome of convulsive status epilepticus: a review. Arch Dis Child. 2007;92(11):948–51. doi: 10.1136/adc.2006.107516. - DOI - PMC - PubMed
    1. Chin RF, Neville BG, Peckham C, Bedford H, Wade A, Scott RC. Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: prospective population-based study. Lancet. 2006;368(9531):222–9. doi: 10.1016/S0140-6736(06)69043-0. - DOI - PubMed
    1. PICANet annual report 2010. http://www.picanet.org.uk/Documentation/. Accessed 15 Dec 2016
    1. Chin RFM, Verhulst L, Neville BGR, Peters MJ, Scott RC. Inappropriate emergency management of status epilepticus in children contributes to need for intensive care. J Neurol Neurosurg Psychiatry. 2004;75(11):1584–8. doi: 10.1136/jnnp.2003.032797. - DOI - PMC - PubMed
    1. Advanced paediatric life support: a practical approach to emergencies (APLS) 6th edition. http://www.alsg.org/uk/Publications. Accessed 15 Dec 2016.

MeSH terms

LinkOut - more resources